Literature DB >> 34021175

Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.

P Jacquerie1, M Henket2, B André3, C Moermans2, D de Seny3, F Gester2, R Louis2, M Malaise3, J Guiot2.   

Abstract

Systemic sclerosis (SSc) is a potentially serious and disabling connective tissue disease specially in case of interstitial lung disease (SSc-ILD). The aim of our study was to evaluate the potential utility of dosing in the induced sputum (IS) and to compare their levels in SSc-ILD and SSc-nonILD patients, as well as in healthy volunteers (HV). IS and sera values were also compared. In a prospective cross-sectional analysis, we studied the IS and serum provided from 25 SSc patients, 15 SSc-nonILD and 10 SSc-ILD, compared to 25 HV. We analyzed sputum cell composition and quantified in the supernatant and corresponding serum by commercially available immunoassays: IGFBP-1, IGFBP-2, IGFBP-3, TGF-β, IL-8, TNF-α, YKL-40, MMP-7 and MMP-9. Lung function was studied by the determination of FEV-1 (%), FVC (%), DLCO (%) and KCO (%). The IS of SSc patients had a lower weight than HV (p<0.05, p<0.01) without any significant difference with regard to the cellularity. IGFBP-1 (p < 0.0001), TGF-β (p < 0.05), IL-8 (p < 0.05), YKL-40 (p < 0.0001) and MMP-7 (p < 0.01) levels were increased in the IS of SSc patients compared to HV. Only IL-8 serum levels (p < 0.001) were increased in SSc patients compared to HV. Neither in IS nor in serum were observed differences between SSc-ILD and SSc-nonILD patients. Correlations were observed between IS IL-8 levels and FEV-1 (%) (r =  = - 0.53, p < 0.01), FVC (%) (r = - 0.51, p < 0.01) and annualized ∆KCO (%) (r = 0.57, p < 0.05), between IS TGF-β levels and annualized ∆FEV-1 (%) (r =  = - 0.57, p < 0.05), between IS IGFBP-2 levels and annualized ∆KCO (%) (r = 0.56, p < 0.05). Our study showed that SSc patients exhibit raised IS levels of IGFBP-1, TGF-β, IL-8, YKL-40 and MMP-7, molecules known to be involved in lung remodeling and fibrotic process, without any significant difference between SSc-ILD and SSc-nonILD patients. IL-8, TGF-β and IGFBP-2 are correlated with lung function in SSc patients which emphasize clinical relevance. IS analysis represents a new approach to understand lung inflammatory process in SSc patients. A longitudinal study is needed to evaluate their pathophysiological relevance.

Entities:  

Year:  2021        PMID: 34021175     DOI: 10.1038/s41598-021-87701-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  47 in total

1.  Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases.

Authors:  M Gilson; D Zerkak; J Wipff; D Dusser; A T Dinh-Xuan; V Abitbol; S Chaussade; P Legmann; A Kahan; Y Allanore
Journal:  Eur Respir J       Date:  2009-06-18       Impact factor: 16.671

2.  [Pulmonary arterial hypertension].

Authors:  J Guiot; G Parzibut; T Weber; L Davin; R Dulgheru; P Lancellotti; R Louis; J L Vachiery
Journal:  Rev Med Liege       Date:  2019-03

3.  [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators].

Authors:  J Guiot; O Cornia; R Louis
Journal:  Rev Med Liege       Date:  2020-05

Review 4.  New developments in scleroderma interstitial lung disease.

Authors:  Kristin B Highland; Richard M Silver
Journal:  Curr Opin Rheumatol       Date:  2005-11       Impact factor: 5.006

5.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

6.  Determinants of morbidity and mortality of systemic sclerosis in Canada.

Authors:  Firas F Al-Dhaher; Janet E Pope; Janine M Ouimet
Journal:  Semin Arthritis Rheum       Date:  2008-08-15       Impact factor: 5.532

7.  Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

Authors:  Eric Hachulla; David Launay; Luc Mouthon; Olivier Sitbon; Alice Berezne; Loïc Guillevin; Pierre-Yves Hatron; Gérald Simonneau; Pierre Clerson; Marc Humbert
Journal:  Chest       Date:  2009-05-08       Impact factor: 9.410

Review 8.  [Pattern of biological changes in interstitial lung diseases].

Authors:  F Gester; B Duysinx; C Von Frenckell; R Louis; J Guiot
Journal:  Rev Med Liege       Date:  2019-01

9.  Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients.

Authors:  L Teixeira; L Mouthon; A Mahr; A Berezné; C Agard; M Mehrenberger; L-H Noël; P Trolliet; C Frances; J Cabane; L Guillevin
Journal:  Ann Rheum Dis       Date:  2007-06-08       Impact factor: 19.103

Review 10.  Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?

Authors:  Erica L Herzog; Aditi Mathur; Andrew M Tager; Carol Feghali-Bostwick; Frank Schneider; John Varga
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.